Our mission at D3 Bio is to build a global biotechnology company that develops innovative and more efficacious medicines for patients in need worldwide.

George Chen, MD

Co-Founder, Chairman & CEO

About D3 Bio

D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated.  We do not just only start with science in the lab. First, we start from pinpointing the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into lab to guide the identification of fit for purpose science and technology, and define our drug development path.  

D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Our portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio.  In fact, it underlies our name: Development leading to Discovery that then leads back to more Development, or D3 Bio.

D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.

Our vision

D3 Bio is to transform the lives of patients worldwide who suffer from the most difficult-to-treat, life threatening or debilitating conditions. Creating break-through precision medicines that match therapies to the disease biomarkers of individual patients, D3 Bio is committed to convert life-threatening cancers into manageable chronic conditions. We envision D3 Bio’s novel therapeutics would satisfy the unmet needs of cancer patients across the globe.

Our team

D3 Bio brings a level of world-class experience at multinational big pharma companies that promises success for the Company’s visionary approach to drug discovery, development and commercialization.  With strong track records in successfully introducing major drugs into the U.S., Chinese and other markets, the D3 Bio team understands the science and market requirements for translational drug development.  Their unique vision for D3 Bio is to create a bridge between insights about the actual clinical needs of patients and the scientific, biomarker-driven research needed to create precision medicines for the world.

George Chen, MD

Co-Founder, Chairman, & CEO

George Chen is an oncologist by training with a successful track record in the world of global pharmaceutical companies.  Prior to founding D3 Bio, Dr. Chen held senior global positions in research, drug development and management at leading institutions, such as the National Institutes of Health, and multinational pharmaceutical companies, such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson and AstraZeneca.  At these organizations he led development and regulatory registrations of blockbuster drugs into the U.S. and Chinese markets, directing more than 70 IND approvals and more than 30 NDAs.  His medical degree is from the Shanghai Medical College of Fudan University and his MBA is from the Wharton School of Business at the University of Pennsylvania.

John Jin, PHD

Co-Founder, CFO, CBO, & Board Member

John Jin was previously a founding partner at Hanne Capital and former VP of Business Development both at BeiGene and at TaiGen Biotechnology (Taiwan). Dr. Jin had been responsible for venture investment, corporate and business development, government affairs, and global cross-border licensing deals for cancer and other drugs within China and internationally. During his early career, Dr. Jin took on various managerial roles at Clearview Projects, a US boutique strategic advisory firm, Eli Lilly and Millennium Pharmaceuticals. Dr. Jin has more than 20 years of experience in cross-border investment and financing, pharmaceutical business development and drug licensing, and research and development. Dr. Jin has a Bachelor of Medicine from Peking University School of Medicine, an MBA from Wharton School of Business at the University of Pennsylvania and a Ph.D. in Immunology from Cornell University School of Medicine.

R&D pipeline

D3Bio has built a pipeline of multiple pre-clinical stage oncology programs, all of which have first-in-class or best-in-class potential and carry foundational properties targeting immune-pathways or tumor driving mutations. D3 Bio owns global rights to all the programs.

In the news

Nov 7, 2022 08:00 AM EST
Shanghai, China—D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or “Company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announced the company’s new research data of its oncology program D3L-001 to be presented at the Society for Immunotherapy of Cancer 2022 (SITC 2022) in Boston, USA. Those data highlight D3 Bio’s pipeline innovations in cancer treatment. 
Learn More
Oct 31, 2022 07:00 AM EST
Shanghai, China—D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or “Company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announced the company’s new research data of its oncology program D3S-001 has been presented at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain. Those data highlight D3 Bio’s pipeline innovations in cancer treatment.
Learn More
BUSINESS WIRE — Press Release
Nov 17, 2020 07:30 AM EST
Global biotech headed by seasoned industry veterans secures backing from world-class investor syndicate. Novel approach to guided drug development utilizes clinical and market insights to identify deficiencies in standards of care and match patients with optimal therapies.
Learn More
May 27, 2022 07:00 AM EST
Shanghai, China — D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or “Company”) is a biotechnology company that focuses on discovery, development and registration of innovative medicines in the fields of oncology and immune-oncology. Today, D3 Bio announced that the company received IND (Investigational New Drug) clearance from US FDA for D3S-001, a potent and selective small molecule inhibitor for the mutant KRAS G12C protein at the end of March. The planned Phase I clinical trial is now ready for initiation in patients with advanced solid tumors harboring the KRAS G12C mutation globally.
Learn More
FIERCE BIOTECH — Nick Paul Taylor
Nov 17, 2020 9:00 AM EST
Learn More

Contact us

For career opportunities: hr@d3bio.com

For collaboration opportunities: bd@d3bio.com


Room 324, 88 MeiLiang Road; MaShan Street; BinHu District, Wuxi, JiangSu

1101, 11/F, Building 1, No.6, Lane 38, Yuanshen Road, Pudong, Shanghai